As multidrug resistance increases alarmingly, polymyxin B and colistin are increasingly
being used in the clinic to treat serious Pseudomonas aeruginosa infections. In this …

Pseudomonas aeruginosa causes serious nosocomial infections, and an important
virulence factor produced by this organism is lipopolysaccharide (LPS). This review …

Lipopolysccharide (LPS) is an integral component of the Pseudomonas aeruginosa cell
envelope, occupying the outer leaflet of the outer membrane in this Gram-negative …

In addition to exhibiting swimming and twitching motility, Pseudomonas aeruginosa is able
to swarm on semisolid (viscous) surfaces. Recent studies have indicated that swarming is a …

Two-component regulatory systems (TCSs) are a major mechanism by which bacteria sense
and respond to changes in their environment. TCSs typically consist of two proteins that …

The Gram-negative opportunistic pathogen Pseudomonas aeruginosa ubiquitously inhabits
soil and water habitats and also causes serious, often antibiotic resistant, infections in …

The polymyxins, colistin (also known as polymyxin E) and polymyxin B, have a unique and
interesting history. Originally introduced in the 1950s for the treatment of infections due to …

In this review, we provide an updated summary on colistin pharmacokinetics and
pharmacodynamics. Colistin is an old molecule that is frequently used as last-line treatment …

In this study, we evaluated how gene expression differs in mature Pseudomonas aeruginosa
biofilms as opposed to planktonic cells by the use of RNA sequencing technology that gives …

The introduction of antimicrobial drugs in medicine gave hope for a future in which all
infectious diseases could be controlled. Decades later it appears certain this will not be the …